New York State Teachers Retirement System Has $510,000 Position in Eagle Pharmaceuticals, Inc. (EGRX)

New York State Teachers Retirement System decreased its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 20.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,557 shares of the specialty pharmaceutical company’s stock after selling 2,200 shares during the period. New York State Teachers Retirement System owned approximately 0.06% of Eagle Pharmaceuticals worth $510,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC boosted its stake in Eagle Pharmaceuticals by 74.4% in the 1st quarter. AQR Capital Management LLC now owns 34,547 shares of the specialty pharmaceutical company’s stock worth $2,865,000 after purchasing an additional 14,743 shares in the last quarter. James Investment Research Inc. bought a new position in Eagle Pharmaceuticals in the 2nd quarter worth about $1,142,000. Argent Capital Management LLC bought a new position in Eagle Pharmaceuticals in the 2nd quarter worth about $686,000. Thrivent Financial For Lutherans boosted its stake in Eagle Pharmaceuticals by 9.5% in the 1st quarter. Thrivent Financial For Lutherans now owns 4,600 shares of the specialty pharmaceutical company’s stock worth $382,000 after purchasing an additional 400 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Eagle Pharmaceuticals by 7,357.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 46,084 shares of the specialty pharmaceutical company’s stock worth $3,634,000 after purchasing an additional 45,466 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “New York State Teachers Retirement System Has $510,000 Position in Eagle Pharmaceuticals, Inc. (EGRX)” was published by Week Herald and is owned by of Week Herald. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://weekherald.com/2017/11/15/new-york-state-teachers-retirement-system-has-510000-position-in-eagle-pharmaceuticals-inc-egrx.html.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) opened at $55.16 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.15 and a current ratio of 5.30. The stock has a market cap of $806.07, a PE ratio of 8.52 and a beta of 1.23. Eagle Pharmaceuticals, Inc. has a one year low of $45.05 and a one year high of $97.15.

Eagle Pharmaceuticals declared that its board has initiated a stock buyback plan on Wednesday, August 9th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the specialty pharmaceutical company to reacquire up to 13.3% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board believes its shares are undervalued.

Several research firms have issued reports on EGRX. Mizuho lowered their target price on shares of Eagle Pharmaceuticals from $40.00 to $37.00 and set an “underperform” rating on the stock in a research note on Wednesday, September 6th. Piper Jaffray Companies set a $118.00 target price on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, July 25th. BidaskClub cut shares of Eagle Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, July 31st. Zacks Investment Research cut shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, July 31st. Finally, Royal Bank Of Canada lowered their target price on shares of Eagle Pharmaceuticals from $94.00 to $81.00 and set an “outperform” rating on the stock in a research note on Thursday, July 27th. Three equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. Eagle Pharmaceuticals has an average rating of “Hold” and an average price target of $62.33.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply